Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Current and emerging unmet needs in R/R multiple myeloma: improving QoL & novel therapeutic options

Karthik Ramasamy • 25 Apr 2023
BSH 2023
Multiple Myeloma
LOCOMMOTION

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses unmet needs in relapsed/refractory (R/R) multiple myeloma, emphasizing the poor quality of life (QoL) experienced by patients. Dr Ramasamy also highlights the need to develop novel agents that not only improve QoL, but also provide a valuable therapeutic benefit. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karthik Ramasamy

1:17
Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy • 20 Dec 2023
2:42
Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry
Karthik Ramasamy • 20 Dec 2023
2:05
RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy • 20 Dec 2023
2:25
OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy • 20 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals